AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)

NEXT STORY
Valneva Announces the Cancellation of Ordinary Shares Held by the Company following Termination of its Liquidity Agreement
PREV STORY
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Coherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today ...

author_avatar
NASDAQ Market News

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA ...

author_avatar
NASDAQ Market News

Akonni Biosystems to Participate in Corporate Access Event in San Francisco, January 7-9, 2019

FREDERICK, Md., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Akonni Biosystems, a molecular diagnostics (MDx) ...

author_avatar
NASDAQ Market News